OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator

Jan 31, 2019

Future Non-Coverage Determination for 4Kscore Test Posted by Novitas

Jan 31, 2019

OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories

Jan 7, 2019

OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action

Dec 27, 2018

OPKO Health Reports Third Quarter 2018 Financial Results

Nov 9, 2018

BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services

Nov 8, 2018

OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018

Nov 8, 2018

OPKO Confirms Resumption of Common Stock Trading on Nasdaq

Sep 14, 2018

OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock

Sep 11, 2018

OPKO Comments on SEC Complaint

Sep 7, 2018